BC
AUPH icon

Broadfin Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Broadfin Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$8.1M Buy
+400,000
New +$3.68M 1.09% 27

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Broadfin Capital's AUPH Position: Q4 2019 in Review

Broadfin Capital opened a new position in Aurinia Pharmaceuticals (AUPH) in Q4 2019: 400,000 shares worth $8.1M. The stake represents 1.09% of the portfolio and ranks #27 among its holdings.

115 funds tracked by Wall St. Rank hold AUPH as of Q4 2019.

  • Broadfin Capital held 400,000 shares of Aurinia Pharmaceuticals worth $8.1M as of Q4 2019.
  • Aurinia Pharmaceuticals was a new Broadfin Capital position in Q4 2019.
  • Aurinia Pharmaceuticals made up 1.09% of Broadfin Capital's portfolio in Q4 2019, its #27 holding.
  • 115 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.